



S

Human Anti-SARS-CoV-2 Spike S1 (CR3022) Neutralizing mAb

Catalog No.	CPC520A CPC520B	Quantity:	50 µg 100 µg
Alternate Names:	Spike glycoprotein, Spike S1 subunit, S glycoprotein, CR3022		
Description:	CR3022, which was previously isolated from a convalescent SARS-CoV–infected patient, is a neutralizing antibody obtained in complex with the receptor-binding domain of the SARS-CoV-2 spike. The antibody binds to an epitope conserved between SARS-CoV-2 and SARS-CoV that is distinct from the receptor-binding site. CR3022 was shown to neutralize SARS-COV in a concerted action with clone CR3014. Presence of both antibodies delivers a blocking action of the SARS-COV RBD-ACE2 interaction, by binding two distinct and functional epitopes.		
UniProt ID:	P0DTC2		
Origin:	Isolated from a convalescent SARS-CoV–infected patient		
Specificity:	Reacts with aa 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318–510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" conformation of the spike protein.		
Bioactivity:	EC ₅₀ = 56.36 ng/ml with SARS-CoV-2 Spike-RBD		
Source:	XtenCHO		
Isotype:	Human IgG1		
Clone:	CR3022		
Concentration:	1.0 mg/ml		
Formulation:	Sterile-filtered PBS, pH 7.5 preservative free.		
Purification:	Protein A affinity chromatography		
Applications:	Neutralizing ELISA: 1:5,000 - 1:10,000 Western blot: suggested dilution 1:1,000 - 1:2,000		
Storage & Stability:	Stable at 2-8°C for 1 week or for up to 1 year at -20°C to -80°C. It is recommended to prepare working aliquots of undiluted product and store -20°C to -80°C.		



NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.